Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Statera Biopharma Inc STAB

Statera BioPharma, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing immunotherapies autoimmune, neutropenia/anemia, emerging viruses and cancers based on a proprietary platform designed to rebalance the body’s immune system and restore homeostasis. It has platform of toll-like receptor (TLR) agonists with TLR4 and TLR9 antagonists, and the TLR5 agonists, Entolimod and GP532. The Company is developing therapies designed to directly elicit within patients a robust and durable response of antigen-specific killer T-cells and antibodies, thereby activating essential immune defenses against autoimmune, inflammatory, infectious diseases, and cancers. It has clinical programs for Crohn’s disease (STAT-201), hematology (Entolimod), pancreatic cancer (STAT-401) and COVID-19 (STAT-205) in addition to potential expansion into fibromyalgia and multiple sclerosis.


GREY:STAB - Post by User

Bullboard Posts
Post by DallasTauruson Jul 06, 2007 9:40am
582 Views
Post# 13045840

Buffalo Facility Appears State of the Art

Buffalo Facility Appears State of the ArtSaw this comment on another message board………The blogger commented on Gudkov's Buffalo lab and facilities as being state of the art. He noted, “I have a friend who lives in Buffalo who recently visited Andrei Gudkov's lab and CBLI's future home facility. Gudkov is now the head of cellular stress at Roswell Park Cancer Center as well as being the Chief Scientific Officer for CBLI. Roswell has a new state of the art facility that any cancer researcher would kill for. CBLI has a similar licensing arrangement with Roswell that they have with the Cleveland Clinic. CBLI gets exclusive rights to anything Gudkov is working on or collaborates on. His lab will have nearly 40 researchers working and cbli gets full benefit. In addition Gudkov is now the head of research at Roswell and it has a $125 million budget. This allows him some sway with other world class researchers in his field even though the other labs are not tied direclty to the cbli deal. This is all in addition to the 30 plus researchers on cbli's employee list. There are very few companies with access to state of the art facilities such as this and also have a market cap below $200 million. My friend who knows an enormous amount about such due diligence was very impressed. This should provide cbli numerous opportunities to test out their cancer drugs.
Bullboard Posts